MAPT and Cognitive impairment: One study demonstrated that CSF markers of neurodegenerative pathology – i.e. tau, phosphorylated-tau (p-tau) and amyloid beta (Aβ)-predicted functional decline at 36 months in cognitively normal subjects and individuals with mild cognitive impairment (MCI),7 while another study found that whole-brain atrophy based on structural MRI and Apolipoprotein E (APOE) ε4 status predicted functional decline in MCI.8